Skip to main content
Premium Trial:

Request an Annual Quote

Digene to Distribute Asuragen s CF Screening Products Worldwide

NEW YORK, April 19 (GenomeWeb News) - Digene will market and distribute cystic fibrosis screening products made by Asuragen, the newly formed molecular diagnostic company spun out of Ambion, the partners said today.

 

Terms of the exclusive, worldwide deal call for Digene to make an up-front payment to Asuragen, and to make additional payments based on regulatory milestones.

 

Asuragen will also develop its next-generation CF test, Signature CF Expand, which will broaden the mutation panel to include ethnic-specific mutations that can be adapted for use in carrier screening and may find additional utility for neonatal and newborn testing. Digene will also distribute this product exclusively and worldwide.

 

In addition, Digene will have the first right of refusal on future genetic test products developed by Asuragen. The Signature products use the Luminex xMAP technology.

 

Asuragen was formed after Applied Biosystems  acquired Ambion's RNA business in March.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.